Association Between Low Trough Levels of Vedolizumab During Induction Therapy for Inflammatory Bowel Diseases and Need for Additional Doses Within 6 Months

Inflammatory Bowel Disease

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

United European Gastroenterol J.

Guidi L, Pugliese D, Tonucci TP, Bertani L, Costa F, Privitera G, Tolusso B, Di Mario C, Albano E, Tapete G, Gremese E, Papa A, Gasbarrini A, Rapaccini GL, Armuzzi A

doi: 10.1177/2050640619873784.

Inflammatory Bowel Disease

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

United European Gastroenterol J.

Hanžel J, Sever N, Ferkolj I, Štabuc B, Smrekar N, Kurent T, Koželj M, Novak G, Compernolle G, Tops S, Gils A, Drobne D

doi: 10.1177/2050640619840211.

Inflammatory Bowel Disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

doi: 10.1097/MEG.

Inflammatory Bowel Disease

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Aliment Pharmacol Ther.

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP; GETECCU study group

doi: 10.1111/apt.14930.

Inflammatory Bowel Disease

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Biologicals.

Ylisaukko-Oja T, Torvinen S, Aaltonen J, Nuutinen H, Blomster T, Jussila A, Pajala M, Salminen K, Moilanen V, Hakala K, Kellokumpu M, Toljamo K, Rautiainen H, Kuisma J, Peräaho M, Molander P, Silvennoinen J, Liukkonen V, Henricson H, Tillonen J, Esterinen M, Nielsen C, Hirsi E, Lääne M, Suhonen UM, Vihriälä I, Mäkelä P, Puhto M, Punkkinen J, Sulonen H, Herrala S, Jokelainen J, Tamminen K, Sipponen T

doi: 10.1016/j.biologicals.

Inflammatory Bowel Disease

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood

Aliment Pharmacol Ther.

Ashton JJ, Borca F, Mossotto E, Coelho T, Batra A, Afzal NA, Phan HTT, Stanton M, Ennis S, Beattie RM

doi: 10.1111/apt.15094.

Inflammatory Bowel Disease

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

United European Gastroenterol J.

Scaldaferri F, Pugliese D, Privitera G, Onali S, Lopetuso LR, Rizzatti G, Settanni CR, Pizzoferrato M, Schiavoni E, Turchini L, Amatucci V, Napolitano D, Bernabei T, Mora V, Laterza L, Papa A, Guidi L, Rapaccini GL, Gasbarrini A, Armuzzi A

doi: 10.1177/2050640620929133.

Inflammatory Bowel Disease

A product review of vedolizumab in inflammatory bowel disease

Hum Vaccin Immunother.

Battat R, Dulai PS, Jairath V, Vande Casteele N

doi: 10.1080/21645515.

Inflammatory Bowel Disease

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease

Dig Dis Sci.

Pratt PK Jr, Nunes D, Long MT, Farraye FA

doi: 10.1007/s10620-

Related content

Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Early vedolizumab trough levels predict combined endoscopic and clinical remission in inflammatory bowel disease

Infliximab trough levels are decreasing over time in patients with inflammatory bowel disease on maintenance treatment with infliximab

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry

Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practice

Increased prevalence of anti-TNF therapy in paediatric inflammatory bowel disease is associated with a decline in surgical resections during childhood

Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre

A product review of vedolizumab in inflammatory bowel disease

Improved Antibody Response to Three Additional Hepatitis B Vaccine Doses Following Primary Vaccination Failure in Patients with Inflammatory Bowel Disease